CRSP Financials: CRISPR Therapeutics AG AI Analysis



Financials

CRSP Financial

CRISPR Therapeutics AG

$55.35

0.5%

$0.27

As of today:May 07, 10:25:11 GMT-4

Overview Forecast Earnings Dividends Financials

Key Stats

Prev.Close

$55.08

Open

$54.52

Day's Range

$53.81 - $55.4

52 week range

$33.03 - $78.48

Volume

261.1K

Avg.Volume

1.8M

Dividend yield

EPS (TTM)

-6.51

Market Cap

$5.3B

What is CRSP?

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. The company is headquartered in Zug, Zug. The company went IPO on 2016-10-19. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The firm aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The firm has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The firm product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.

Features

Markets

News

Income

Balance sheet

Cash flow

Annual

Quarterly

CRSP Income

Financials in millions USD. Fiscal year is February - January.

Breakdown	TTM	12/31/2025	09/30/2025	06/30/2025	03/31/2025	12/31/2024
Revenue	3	0	0	0	0	35
Revenue Growth (YoY)	-92%	-100%	--	--	--	-83%
Cost of Revenue	--	--	--	--	--	--
Gross Profit	--	--	--	--	--	--
Selling, General & Admin	287	72	74	64	76	18
Research & Development	284	83	58	69	72	82
Operating Expenses	571	155	132	133	149	100
Other Non Operating Income (Expenses)	86	24	26	22	13	27
Pretax Income	-577	-129	-105	-207	-134	-36
Income Tax Expense	3	0	0	1	1	0
Net Income	-581	-130	-106	-208	-135	-37
Net Income Growth	59%	250.99%	25%	65%	16%	-142%
Shares Outstanding (Diluted)	95.32	95.32	91.3	87.06	85.93	85.47
Shares Change (YoY)	12%	12%	7%	3%	5%	7%
EPS (Diluted)	-6.1	-1.37	-1.16	-2.39	-1.58	-0.43
EPS Growth	43%	214%	16%	61%	11%	-139%
Free Cash Flow	-370	-93	-84	-138	-54	-50
Free Cash Flow Per Share	--	--	--	--	--	--
Gross Margin	--	--	--	--	--	--
Operating Margin	-18,933.33%	0%	0%	0%	0%	-182.85%
Profit Margin	-19,366.66%	0%	0%	0%	0%	-105.71%
Free Cash Flow Margin	-12,333.33%	0%	0%	0%	0%	-142.85%
EBITDA	-549	-149	-128	-129	-144	-60
EBITDA Margin	-18,300%	0%	0%	0%	0%	-171.42%
D&A For EBITDA	19	5	4	4	4	4
EBIT	-568	-154	-132	-133	-148	-64
EBIT Margin	-18,933.33%	0%	0%	0%	0%	-182.85%
Effective Tax Rate	-0.51%	0%	0%	-0.48%	-0.74%	0%

Follow-Up Questions

What are CRISPR Therapeutics AG's key financial statements?



According to the latest financial statement (Form-10K), CRISPR Therapeutics AG has a total asset of $0, Net loss of $0

What are the key financial ratios for CRSP?



CRISPR Therapeutics AG's Current ratio is 0, has a Net margin is 0, sales per share of $0.

How is CRISPR Therapeutics AG's revenue broken down by segment or geography?



CRISPR Therapeutics AG largest revenue segment is Genome-editing Technology, at a revenue of 3,510,000 in the most earnings release.For geography, Switzerland and United States is the primary market for CRISPR Therapeutics AG, at a revenue of 3,510,000.

Is CRISPR Therapeutics AG profitable?



no, according to the latest financial statements, CRISPR Therapeutics AG has a net loss of $0

Does CRISPR Therapeutics AG have any liabilities?



no, CRISPR Therapeutics AG has liability of 0

How many outstanding shares for CRISPR Therapeutics AG?



CRISPR Therapeutics AG has a total outstanding shares of 0

CRISPR Therapeutics AG (CRSP) Financial

CRSP Stock Price Chart